Theodore E. Hebert

Array ( [id] => 17356813 [patent_doc_number] => 20220017609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIR [patent_app_type] => utility [patent_app_number] => 17/193933 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342082 [patent_doc_number] => 20220008413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/193795 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761485 [patent_doc_number] => 20220235097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => METHODS OF TREATMENT AND RELATED COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/430171 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17073708 [patent_doc_number] => 11110087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor [patent_app_type] => utility [patent_app_number] => 17/187468 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13970 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060125 [patent_doc_number] => 11104712 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Methods for modulating an immune response [patent_app_type] => utility [patent_app_number] => 17/180064 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 100 [patent_figures_cnt] => 192 [patent_no_of_words] => 97992 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179508 [patent_doc_number] => 20250263466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/760032 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868537 [patent_doc_number] => 20210162004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER [patent_app_type] => utility [patent_app_number] => 17/161253 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20756196 [patent_doc_number] => 12648943 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors [patent_app_type] => utility [patent_app_number] => 17/792675 [patent_app_country] => US [patent_app_date] => 2021-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 23516 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 578 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853517 [patent_doc_number] => 20210154262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => ENDOPLASMIC RETICULUM STRESS AS A PREDICTIVE TOOL IN CANCER THERAPY AND A COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/157126 [patent_app_country] => US [patent_app_date] => 2021-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458678 [patent_doc_number] => 20220071982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => METHODS AND USES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/153345 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17149519 [patent_doc_number] => 11142582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-12 [patent_title] => Anti-CD40 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/149209 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 21254 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 463 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200410 [patent_doc_number] => 12403175 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Methods for treating pemphigus disorders [patent_app_type] => utility [patent_app_number] => 17/144481 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 38 [patent_no_of_words] => 28450 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18285794 [patent_doc_number] => 20230101266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTI-TROP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND APPLICATION OF THE SAME [patent_app_type] => utility [patent_app_number] => 17/758269 [patent_app_country] => US [patent_app_date] => 2020-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468899 [patent_doc_number] => 20230203182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Composition and Use of Engineered Monoclonal Antibodies Refractory to Tumor Immuno-Suppressive Factors [patent_app_type] => utility [patent_app_number] => 17/789746 [patent_app_country] => US [patent_app_date] => 2020-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18184886 [patent_doc_number] => 20230045616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => CANCER TREATMENT METHOD AND MEDICINE [patent_app_type] => utility [patent_app_number] => 17/789327 [patent_app_country] => US [patent_app_date] => 2020-12-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806156 [patent_doc_number] => 20210128709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => COMBINATORIAL ANDROGEN DEPRIVATION WITH AN ANDROGEN RECEPTOR VACCINE [patent_app_type] => utility [patent_app_number] => 17/130532 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310207 [patent_doc_number] => 20230114107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => COMBINATION ANTI-CANCER THERAPIES WITH INDUCERS OF IRON-DEPENDENT CELLULAR DISASSEMBLY [patent_app_type] => utility [patent_app_number] => 17/787287 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776633 [patent_doc_number] => 20210113710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 17/118228 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17329234 [patent_doc_number] => 11219675 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-11 [patent_title] => Methods of cancer treatment using activated T cells [patent_app_type] => utility [patent_app_number] => 17/115620 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 82 [patent_no_of_words] => 82179 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18271114 [patent_doc_number] => 20230092356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => NOVEL AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/782526 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782526 [rel_patent_id] =>[rel_patent_doc_number] =>)